

## SPECIALTY GUIDELINE MANAGEMENT

### EXJADE (deferasirox; tablets for suspension) JADENU (deferasirox; tablets)

#### POLICY

#### I. INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

##### FDA-Approved Indications

1. Chronic iron overload due to blood transfusions (transfusional iron overload)
2. Chronic iron overload in patients with non-transfusion-dependent thalassemia (NTDT) syndromes

All other indications are considered experimental/investigational and are not a covered benefit.

#### II. INITIAL CRITERIA FOR APPROVAL

##### **A. Chronic Iron Overload due to Blood Transfusions (transfusional iron overload)**

Indefinite authorization may be granted for the treatment of chronic iron overload due to blood transfusions when a pretreatment serum ferritin level is greater than 1000 mcg/L.

##### **B. Chronic Iron Overload in Patients with Non-transfusion Dependent Thalassemia Syndromes**

Authorization of 12 months may be granted for the treatment of chronic iron overload in members with non-transfusion dependent thalassemia syndromes.

#### III. CONTINUATION OF THERAPY

All members (including new members) requesting authorization for continuation of therapy must meet ALL initial authorization criteria.

#### IV. REFERENCES

1. Exjade [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; August 2016.
2. Jadenu [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; August 2016.
3. Micromedex Solutions [database online]. Truven Health Analytics, Inc. Ann Arbor, MI. Available at: [www.micromedexsolutions.com](http://www.micromedexsolutions.com). Accessed November 18, 2016.
4. AHFS DI (Adult and Pediatric) [database online]. Lexi-Comp, Inc. Hudson, OH. Available at: [http://online.lexi.com/lco/action/index/dataset/complete\\_ashp](http://online.lexi.com/lco/action/index/dataset/complete_ashp) [available with subscription]. Accessed November 18, 2016.
5. Clinical Pharmacology [Internet]. Elsevier. Tampa (FL). Available from: <http://www.clinicalpharmacology.com>. Accessed November 18, 2016.
6. Cappellini MD, Cohen A, Porter J, et al. Guidelines for the management of transfusion dependent thalassaemia (TDT) 3<sup>rd</sup> Edition [Internet]. *Thalassaemia International Federation* 2014;20:1-253.
7. Hoffbrand AV, Taher A, Cappellini MD. How I treat transfusional iron overload. *Blood* 2012;120(18):3657-69.
8. Taher A, Vichinsky E, Musallam K, et al. Guidelines for the management of non-transfusion dependent thalassaemia (NTDT). *Thalassaemia International Federation* 2013;19:1-120.